JP2016505546A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505546A5
JP2016505546A5 JP2015545453A JP2015545453A JP2016505546A5 JP 2016505546 A5 JP2016505546 A5 JP 2016505546A5 JP 2015545453 A JP2015545453 A JP 2015545453A JP 2015545453 A JP2015545453 A JP 2015545453A JP 2016505546 A5 JP2016505546 A5 JP 2016505546A5
Authority
JP
Japan
Prior art keywords
kabat
cdr
vegf
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015545453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505546A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/072335 external-priority patent/WO2014085654A1/en
Publication of JP2016505546A publication Critical patent/JP2016505546A/ja
Publication of JP2016505546A5 publication Critical patent/JP2016505546A5/ja
Ceased legal-status Critical Current

Links

JP2015545453A 2012-11-30 2013-11-27 抗vegf抗体及びこれらの使用 Ceased JP2016505546A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732256P 2012-11-30 2012-11-30
US61/732,256 2012-11-30
PCT/US2013/072335 WO2014085654A1 (en) 2012-11-30 2013-11-27 Anti-vegf antibodies and their uses

Publications (2)

Publication Number Publication Date
JP2016505546A JP2016505546A (ja) 2016-02-25
JP2016505546A5 true JP2016505546A5 (https=) 2017-01-12

Family

ID=49765713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545453A Ceased JP2016505546A (ja) 2012-11-30 2013-11-27 抗vegf抗体及びこれらの使用

Country Status (11)

Country Link
US (2) US20140154255A1 (https=)
EP (1) EP2925778B1 (https=)
JP (1) JP2016505546A (https=)
CN (1) CN104903348A (https=)
AU (1) AU2013352127A1 (https=)
BR (1) BR112015012538A2 (https=)
CA (1) CA2892164A1 (https=)
ES (1) ES2649966T3 (https=)
HK (1) HK1215446A1 (https=)
MX (1) MX2015006859A (https=)
WO (1) WO2014085654A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6800141B2 (ja) * 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
RU2763916C2 (ru) * 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017119434A1 (ja) * 2016-01-06 2017-07-13 株式会社オーダーメードメディカルリサーチ Vegfとnrp1との結合を阻害する抗体
JP7046828B2 (ja) * 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 滲出型加齢性黄斑変性の治療のための組成物
CN110248674B (zh) 2016-09-07 2021-10-26 萨辛生命科学有限公司 针对vegf的合成抗体及其用途
JP7337698B2 (ja) 2017-02-28 2023-09-04 シージェン インコーポレイテッド コンジュゲート化のためのシステイン突然変異抗体
WO2018213064A1 (en) 2017-05-19 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfer2 for cancer immunotherapy
CN110283248B (zh) * 2018-01-05 2020-07-28 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN109053895B (zh) 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111363038A (zh) * 2020-03-26 2020-07-03 北京纽安博生物技术有限公司 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
WO2022197866A1 (en) * 2021-03-16 2022-09-22 City Of Hope Anti-hvem antibodies
US20250367255A1 (en) 2021-11-08 2025-12-04 Pfizer Inc. Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
WO2000037502A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
US6979559B2 (en) 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
PL205897B1 (pl) 2000-12-14 2010-06-30 Genentech Inc Komórka gospodarza E. coli i sposób wytwarzania polipeptydu
WO2002061090A2 (en) 2000-12-14 2002-08-08 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
CA2369893A1 (en) 2001-02-12 2002-08-12 Warner-Lambert Company Vegf responsive cell-based assay for determining vegf bioactivity
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20040010376A1 (en) 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US20030022240A1 (en) 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1573002A4 (en) 2002-02-11 2008-07-16 Genentech Inc ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION SPEEDS
CN1672160B (zh) 2002-05-20 2010-06-09 埃博马可西斯公司 基于前导抗体的结构构建抗体文库的方法
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
EP1648940B1 (en) 2003-07-28 2016-04-27 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US20080292628A1 (en) 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
JP2008515970A (ja) 2004-10-12 2008-05-15 アンプロテイン コーポレイション キメラタンパク質
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US20080207467A1 (en) 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
JP2009515516A (ja) 2005-11-14 2009-04-16 バイオレン・インク 推定成熟cdrのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
WO2007059336A1 (en) 2005-11-18 2007-05-24 Nextrom Oy Method and apparatus for manufacturing water-free optical fiber preforms
WO2007062037A2 (en) 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
EP1981541A4 (en) 2006-01-23 2011-09-28 Errico Joseph P METHODS AND COMPOSITIONS FOR DEVELOPING A TARGET MEDICINE
JP2009542232A (ja) 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および/または内皮層を通過するscFv抗体
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2280997A2 (en) 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
PE20120622A1 (es) * 2009-06-17 2012-05-26 Abbott Biotherapeutics Corp Anticuerpos anti-vegf y sus usos
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
EP3223014B1 (en) 2010-09-24 2018-12-05 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
AR083672A1 (es) * 2010-11-02 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2014078866A2 (en) 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses

Similar Documents

Publication Publication Date Title
JP2016505546A5 (https=)
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
JP2018183173A5 (https=)
JP2018505177A5 (https=)
JP2016512551A5 (https=)
JP2012530496A5 (https=)
JP2011046732A5 (https=)
JP2021514973A5 (https=)
JP2017534577A5 (https=)
JP2019501883A5 (https=)
JP2016536020A5 (https=)
JP2023134618A5 (https=)
JP2019536806A5 (https=)
JP2020520370A5 (https=)
JP2015509947A5 (https=)
JP2018510617A5 (https=)
JP2018506277A5 (https=)
JP2018035138A5 (https=)
JP2024056687A5 (https=)
JP2011506483A5 (https=)
JP2014158469A5 (https=)
JP2017535257A5 (https=)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2018507220A5 (https=)
RU2017102514A (ru) Гуманизированные анти-тау-антитела